Cystic Fibrosis — Genetics and Pathophysiology

Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in the CFTR gene (cystic fibrosis transmembrane conductance regulator) on chromosome 7q31, resulting in defective chloride channel function and pathologic thick, viscous secretions in multiple organ systems. The disease affects approximately 1 in 2,500–3,500 live births in Caucasian populations (highest incidence in Northern European ancestry), with significantly lower prevalence in African and Asian populations. CF is the most common life-limiting autosomal recessive disorder in people of European descent and presents with progressive pulmonary disease (bronchiectasis), pancreatic insufficiency, malabsorption, and CF-related diabetes. Understanding the molecular pathophysiology of CFTR dysfunction is essential for clinical practice, as novel targeted therapies (modulator compounds) have dramatically improved outcomes and are now cornerstone treatments. This entry focuses on the biochemical and genetic foundation of CF, which underpins diagnosis, prognostication, and individualized therapeutic strategies including emerging CFTR modulators.

The pathophysiology of cystic fibrosis fundamentally centers on loss-of-function mutations in the CFTR gene and the resulting defective or absent chloride channel protein, which cascades into dysregulation of electrolyte and fluid secretion across epithelial tissues.

The CFTR gene spans 250 kilobases and encodes a 1,480 amino acid transmembrane protein functioning as a cAMP-regulated chloride channel. Over 2,000 disease-causing mutations have been identified, classified into six functional classes: (1) Class I mutations (nonsense, frameshift, splice site defects) result in absent or severely truncated protein due to premature termination codons; (2) Class II mutations (most common, exemplified by ΔF508, a deletion of phenylalanine at position 508 accounting for ~70% of CF alleles globally) produce full-length CFTR with defective protein folding, trafficking, and endoplasmic reticulum (ER) retention, leading to degradation via the unfolded protein response and proteasome pathway; (3) Class III mutations produce normally trafficking but non-functional channel protein (defective channel gating); (4) Class IV mutations yield partially functional channel with reduced conductance; (5) Class V mutations reduce the amount of normal CFTR produced through promoter or splicing defects; and (6) Class VI mutations destabilize the channel protein at the cell membrane. These classifications have direct implications for therapeutic responsiveness: Class II mutations (including ΔF508) are amenable to CFTR modulators (potentiators and correctors), while Class I mutations require different therapeutic approaches (e.g., readthrough agents).

Under normal conditions, the CFTR chloride channel is localized to the apical membrane of epithelial cells and is activated by increased intracellular cAMP (downstream of β-adrenergic signaling). When activated, CFTR permits chloride ions (Cl⁻) to move down their electrochemical gradient from the intracellular space into the airway lumen. This chloride secretion is essential for osmotic fluid secretion: the positive charge imbalance created by chloride efflux is immediately compensated by paracellular sodium (Na⁺) movement, drawing water across the epithelium into the lumen via aquaporins, thereby hydrating the secreted mucus layer. In CF, defective CFTR function severely impairs chloride secretion into the lumen. Consequently, the sodium-potassium-ATPase (Na⁺/K⁺-ATPase) continues to pump sodium into the intracellular compartment (and potassium out), but without compensatory chloride loss from the lumen-side, sodium accumulates intracellularly and becomes reabsorbed via epithelial sodium channels (ENaCs—epithelial sodium channels) on the apical membrane. This paradoxical net sodium reabsorption is exacerbated because CF cells have elevated ENaC expression and activity (loss of normal CFTR-mediated inhibition of ENaC). The net result is a marked reduction in fluid secretion into the airway lumen, causing dehydration of the mucus layer. Additionally, the mucus-lining fluid becomes hyperosmolar due to the abnormal electrolyte composition, further impairing mucociliary clearance.

The dehydrated mucus in CF is not only reduced in volume but also altered in biochemical composition. Normal airway secretions contain proteases (including neutrophil elastase), antimicrobial peptides (lysozyme, lactoferrin), and immunoglobulins that maintain immune homeostasis. In CF, the dysregulated electrolyte environment and acidic pH (due to lactic acid production by CF airway epithelial cells and impaired pH regulation) promote a pro-inflammatory milieu. The mucus becomes increasingly acidic (pH often <6.5 versus normal pH ~7.4), which paradoxically activates neutrophil elastase while inactivating important antimicrobial proteins like lactoferrin and lysozyme. This creates a "perfect storm" for bacterial colonization: thick, adherent mucus plugs obstruct airways, preventing mucociliary clearance; reduced antimicrobial activity permits bacterial overgrowth; and the acidic, protease-rich environment drives progressive tissue damage. The abnormal mucus composition also includes elevated levels of mucins (MUC5AC), free fatty acids (from impaired lipid absorption), and oxidative stress markers, all contributing to airway inflammation and remodeling.

Beyond its role as a chloride channel, CFTR has critical functions in innate immunity and bacterial killing that are independent of its ion-channel activity. CFTR is expressed on neutrophils, macrophages, and dendritic cells, where it participates in chemotaxis, phagocytosis, and antimicrobial peptide secretion. CFTR-deficient cells demonstrate impaired inflammatory cell recruitment, reduced production of the antimicrobial peptide LL-37 (cathelicidin) by airway epithelial cells, and decreased autophagy-mediated killing of intracellular pathogens. Furthermore, Pseudomonas aeruginosa (PA), the archetypal CF pathogen, has evolved to exploit the CF airway environment: it produces biofilms composed of alginate (a capsular polysaccharide), which protects the organism from antibiotics and host immune factors. The acidity, mucus-bound state, and immunosuppressive local environment in CF airways provide ideal conditions for PA biofilm formation and chronic persistence, leading to the characteristic chronic productive cough and progressive lung destruction.

CFTR is abundantly expressed in pancreatic ductal epithelium, where it mediates chloride-dependent, bicarbonate-rich fluid secretion into the pancreatic ducts. In CF, impaired ductal fluid secretion results in reduced bicarbonate delivery to the small intestine, allowing gastric acid to overwhelm the intestinal buffering capacity. Simultaneously, the reduced aqueous phase in pancreatic secretions leads to inspissation (thickening) and plugging of pancreatic ducts with mucus. The resulting ductal obstruction causes increased intraductal pressure, parenchymal atrophy, and eventual fibrosis and fatty replacement of pancreatic tissue—a process termed pancreatic insufficiency (PI). Approximately 85% of CF patients develop pancreatic insufficiency by late childhood or adulthood. This is functionally manifested as markedly reduced secretion of pancreatic digestive enzymes (amylase, lipase, proteases), resulting in severe malabsorption of fats, fat-soluble vitamins (A, D, E, K), and proteins. The steatorrhea (fatty, foul-smelling stools) is a hallmark symptom and directly reflects pancreatic enzyme deficiency combined with abnormal bile acid metabolism and impaired lipid emulsification.

CFTR dysfunction in intestinal epithelium leads to abnormal fluid and electrolyte secretion similar to airway disease. Meconium ileus (in neonates) results from inspissated, putty-like meconium in the distal ileum, caused by abnormal chloride-dependent water secretion and increased intestinal mucus viscosity. In older CF patients, distal intestinal obstruction syndrome (DIOS) can occur from accumulation of viscous secretions in the distal ileum and proximal colon. Additionally, CF affects the biliary system: CFTR mutations in bile duct epithelium impair chloride-dependent bicarbonate secretion, reducing protective bicarbonate in bile. This results in reduced pH and increased bile acid saturation, promoting bile duct plugging and eventual biliary cirrhosis. Approximately 5–10% of CF patients develop advanced cirrhosis with portal hypertension.

Progressive pancreatic fibrosis inevitably damages the islets of Langerhans, leading to CF-related diabetes (CFRD), which affects up to 40% of adults with CF. CFRD is distinct from both Type 1 and Type 2 diabetes: it results from loss of both β-cells (causing insulin deficiency) and α-cells (causing impaired glucagon response), with preserved insulin sensitivity. The pathophysiology involves both chronic pancreatitis (inflammatory destruction of islets) and direct CFTR-dependent dysfunction of islet cell physiology. CFRD significantly worsens CF prognosis and pulmonary outcomes, likely due to impaired immune function and increased inflammatory burden associated with hyperglycemia.

In the distal pancreatic duct, CFTR mediates the chloride-bicarbonate exchange mechanism that is essential for secretion of alkaline pancreatic juice (pH 8.3–8.4). This high-pH secretion is crucial for neutralizing gastric acid and creating an optimal pH for pancreatic enzyme function and bile acid activation in the duodenum. CF patients lack this protective bicarbonate-rich secretion, resulting in an acidic duodenal environment that inactivates pancreatic lipase (optimal pH 6–7) and inhibits pancreatic protease activity. This further exacerbates malabsorption and contributes to the pathognomonic finding of steatorrhea and protein malnutrition in CF.

Cystic fibrosis is caused exclusively by mutations in the CFTR gene (CFTR, cystic fibrosis transmembrane conductance regulator) on chromosome 7q31. The disease requires biallelic mutations (two defective CFTR alleles) for clinical manifestation, following autosomal recessive inheritance. Heterozygous carriers (one mutated allele, one normal allele) are asymptomatic but can be identified through carrier screening programs. Over 2,000 distinct pathogenic variants have been catalogued in the CF Foundation's Clinical and Functional Translation of CFTR (CFTR2) database. The most common mutation worldwide is ΔF508 (deletion of phenylalanine at codon 508), accounting for approximately 70% of CF alleles in European populations but <20% in some Asian and African populations, reflecting population-specific mutation spectra. Class I mutations (nonsense, frameshift) occur at high frequency in Ashkenazi Jewish populations, while Class IV mutations (reduced conductance) are more prevalent in Hispanic and some Mediterranean populations. The specific CFTR genotype partially predicts disease severity and phenotype: Class I mutations typically cause severe CF with pancreatic insufficiency and earlier pulmonary disease onset, while Class IV mutations (e.g., R117H) may present with milder, atypical CF phenotypes or isolated pancreatic sufficiency.

Beyond CFTR genotype, multiple genetic and environmental modifiers influence CF disease severity and progression. TGFB1 (transforming growth factor β1) polymorphisms, TNF (tumor necrosis factor α) variants, and polymorphisms in the MBL2 gene (mannose-binding lectin, involved in innate immunity) have been associated with more rapid lung disease decline. SERPINA1 variants (alpha-1 antitrypsin gene) may modify protease-antiprotease imbalance in CF airways. Polymorphisms in genes encoding IL-8 (interleukin-8, a key neutrophil chemoattractant) and its receptors have also shown association with CF lung disease severity in some populations. Additionally, variants in the CFTR gene itself outside the main coding region (e.g., promoter SNPs affecting CFTR expression levels) may influence residual CFTR function and phenotype. These modifier effects highlight the complex, multigenic nature of CF pathophysiology and explain significant variability in disease severity even among patients with identical CFTR mutations.

While CF is a monogenic disease caused by CFTR mutations, environmental exposures critically influence disease progression. Chronic bacterial respiratory tract infection, particularly with Pseudomonas aeruginosa (PA), is the dominant driver of progressive airway destruction. PA biofilm colonization is facilitated by the CF airway microenvironment and is nearly universal in CF patients by adulthood (85–90% prevalence). Other common CF pathogens include Burkholderia cepacia complex (associated with rapid pulmonary decline in some strains), Staphylococcus aureus (especially in younger patients and MRSA in some centers), Haemophilus influenzae, and the emerging pathogen Mycobacterium abscessus. Environmental smoke exposure (active or secondhand) accelerates lung function decline. Malnutrition acts as a powerful modifier: poor nutritional status predicts faster lung disease progression, impaired immune function, and worse outcomes. Adherence to airway clearance therapy and pancreatic enzyme supplementation are modifiable behavioral factors that significantly impact prognosis.

CF presents with a spectrum of severity across the lifespan. Neonatal screening programs now identify CF before symptoms develop, allowing early intervention and potentially improved long-term outcomes. Conversely, CF diagnosed in adulthood (often as "atypical" or mild CF) typically represents Class IV or Class V mutations with residual CFTR function or pancreatic sufficiency (PI-negative phenotype). Advanced CFTR modulator therapy, introduced in recent years, has become a critical "environmental factor" modifying disease trajectory: homozygous ΔF508 patients treated with ivacaftor/lumacaftor or elexacaftor/tezacaftor/ivacaftor (Trikafta) show marked improvements in lung function and slowed decline in FEV₁, representing a paradigm shift in CF therapeutics.

Chronic productive cough is the cardinal pulmonary symptom of CF, reflecting obstruction of airways by thick mucus and chronic bacterial colonization. The cough is often worse in the morning and after exertion. As CF progresses, patients develop progressive dyspnea on exertion, initially with activity and eventually at rest. Recurrent and chronic respiratory tract infections (bronchitis, pneumonia) are hallmark features; patients may experience frequent exacerbations requiring hospitalization and intravenous antibiotics. On auscultation, inspiratory crackles and wheezes are common, reflecting airway secretions and reactive airway disease. Progressive airway obstruction leads to bronchiectasis (bronchial dilatation and destruction visible on high-resolution CT chest), which is the pathologic hallmark of CF lung disease. Bronchiectasis creates a vicious cycle of impaired clearance, infection, and inflammation. Complications of advanced lung disease include hemoptysis (from bronchial artery hypertrophy and erosion), pneumothorax (from rupture of subpleural blebs), and cor pulmonale (right heart failure from pulmonary hypertension). CF patients often develop CF-related asthma or reactive airway disease, manifesting as increased airflow obstruction and responsiveness to bronchodilators.

Pancreatic insufficiency is present in ~85% of CF patients and manifests clinically as severe steatorrhea (fatty, foul-smelling stools with excessive fecal fat; >7 g/day is diagnostic), diarrhea, and failure to thrive despite adequate caloric intake in infants and young children. Malabsorption of fat-soluble vitamins (A, D, E, K) leads to